Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.[L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858]
Synonyms
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
trans-Amcha
Trans AMCHA
Tranexmic acid
Tranexamsaeure
Acide tranéxamique
TXA
trans-Tranexamic acid
Tranhexamic acid
Tranexamic acid
Acidum tranexamicum
trans-4-aminomethylcyclohexane-1-carboxylic acid
ácido tranexámico
Brand Names
Skinmd Laboratories Pure Whitenol Intensive
SKINMD LABORATORIES ReviTox blue
Erfa-tranexamic
Cyklokapron
Tranexamic Acid Injection, USP
M-tranexamic Acid
Lysteda
Skinmd Laboratories Pure Whitenol Serum
Tranexamic acid
Tranexamic Acid Injection
Gd-tranexamic Acid
Mar-tranexamic Acid
Tranexamic Acid Tablets
Pure Whitenol Serum
Tranexamic Acid in Sodium Chloride
Tranexamic Acid In Sodium Chloride
Cyklokapron 500 mg
Tranexamic Acid Injection BP
Liquid
Cyklokapron 100 mg/ml
Tranexamic Acid
Indication
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema,[L31883] cyclic heavy menstrual bleeding in premenopausal females,[L31858] and other instances of significant bleeding in the context of hyperfibrinolysis.[L31883] Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.[L31853]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682